183 related articles for article (PubMed ID: 23609977)
1. Impact of the K24N mutation on the transactivation domain of p53 and its binding to murine double-minute clone 2.
Zhan YA; Wu H; Powell AT; Daughdrill GW; Ytreberg FM
Proteins; 2013 Oct; 81(10):1738-47. PubMed ID: 23609977
[TBL] [Abstract][Full Text] [Related]
2. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
Levy R; Gregory E; Borcherds W; Daughdrill G
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
[TBL] [Abstract][Full Text] [Related]
3. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
4. Conservation of Affinity Rather Than Sequence Underlies a Dynamic Evolution of the Motif-Mediated p53/MDM2 Interaction in Ray-Finned Fishes.
Mihalič F; Arcila D; Pettersson ME; Farkhondehkish P; Andersson E; Andersson L; Betancur-R R; Jemth P
Mol Biol Evol; 2024 Feb; 41(2):. PubMed ID: 38301272
[TBL] [Abstract][Full Text] [Related]
5. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
7. Evolution of affinity between p53 transactivation domain and MDM2 across the animal kingdom demonstrates high plasticity of motif-mediated interactions.
Mihalič F; Åberg E; Farkhondehkish P; Theys N; Andersson E; Jemth P
Protein Sci; 2023 Jul; 32(7):e4684. PubMed ID: 37211711
[TBL] [Abstract][Full Text] [Related]
8. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways.
Ha JH; Shin JS; Yoon MK; Lee MS; He F; Bae KH; Yoon HS; Lee CK; Park SG; Muto Y; Chi SW
J Biol Chem; 2013 Mar; 288(10):7387-98. PubMed ID: 23316052
[TBL] [Abstract][Full Text] [Related]
9. Structural divergence is more extensive than sequence divergence for a family of intrinsically disordered proteins.
Borcherds W; Kashtanov S; Wu H; Daughdrill GW
Proteins; 2013 Oct; 81(10):1686-98. PubMed ID: 23606624
[TBL] [Abstract][Full Text] [Related]
10. Direct observations of conformational distributions of intrinsically disordered p53 peptides using UV Raman and explicit solvent simulations.
Xiong K; Zwier MC; Myshakina NS; Burger VM; Asher SA; Chong LT
J Phys Chem A; 2011 Sep; 115(34):9520-7. PubMed ID: 21528875
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case.
Ithuralde RE; Turjanski AG
PLoS One; 2016; 11(1):e0144284. PubMed ID: 26742101
[TBL] [Abstract][Full Text] [Related]
12. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
13. The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif.
Xu H; Ye H; Osman NE; Sadler K; Won EY; Chi SW; Yoon HS
Biochemistry; 2009 Dec; 48(51):12159-68. PubMed ID: 19916559
[TBL] [Abstract][Full Text] [Related]
14. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study.
Lee HJ; Srinivasan D; Coomber D; Lane DP; Verma CS
Cell Cycle; 2007 Nov; 6(21):2604-11. PubMed ID: 17957142
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanism of the interaction between MDM2 and p53.
Schon O; Friedler A; Bycroft M; Freund SM; Fersht AR
J Mol Biol; 2002 Oct; 323(3):491-501. PubMed ID: 12381304
[TBL] [Abstract][Full Text] [Related]
17. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
18. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
[TBL] [Abstract][Full Text] [Related]
19. NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain.
Vise PD; Baral B; Latos AJ; Daughdrill GW
Nucleic Acids Res; 2005; 33(7):2061-77. PubMed ID: 15824059
[TBL] [Abstract][Full Text] [Related]
20. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
Song Q; Liu XQ; Rainey JK
Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
